ASND (Ascendis Pharma AS) Cyclically Adjusted Book per Share: $8.40 (As of Mar. 2026)


ASND Ascendis Pharma AS ASND
37 GF Score
Price $260.75
! 1 Warning Sign
View Full Analysis

What is Ascendis Pharma AS Cyclically Adjusted Book per Share?

Ascendis Pharma AS ASND -0.24% 37 Cyclically Adjusted Book per Share is $8.40 as of Mar. 2026. GuruFocus rates ASND with a GF Score™ of 37/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Ascendis Pharma AS's adjusted book value per share for the three months ended in Mar. 2026 was $9.131. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $8.40 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Ascendis Pharma AS's average Cyclically Adjusted Book Growth Rate was -6.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-06-27), Ascendis Pharma AS's current stock price is $260.75. Ascendis Pharma AS's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $8.40. Ascendis Pharma AS's Cyclically Adjusted PB Ratio of today is 31.04.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Ascendis Pharma AS was 31.04. The lowest was 25.05. And the median was 27.39.


Ascendis Pharma AS  (NAS:ASND) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Ascendis Pharma AS's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=260.75/8.40
=31.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Ascendis Pharma AS was 31.04. The lowest was 25.05. And the median was 27.39.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Ascendis Pharma AS Cyclically Adjusted Book per Share Related Terms


Ascendis Pharma AS Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Ascendis Pharma AS's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma AS Cyclically Adjusted Book per Share Chart

Ascendis Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 9.98 9.20 8.31

Ascendis Pharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.01 8.77 8.58 8.31 8.40

ASND vs SMMT, BBIO, JAZZ: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Ascendis Pharma AS's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma AS Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma AS's Cyclically Adjusted PB Ratio falls into.


ASND
37GF Score
Ascendis Pharma AS ASND
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascendis Pharma AS Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ascendis Pharma AS's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=9.131/121.2000*121.2000
=9.131

Current CPI (Mar. 2026) = 121.2000.

Ascendis Pharma AS Quarterly Data

Book Value per Share CPI Adj_Book
201606 4.065 100.600 4.897
201609 3.312 100.200 4.006
201612 5.746 100.300 6.943
201703 5.095 101.200 6.102
201706 4.372 101.200 5.236
201709 6.625 101.800 7.888
201712 5.990 101.300 7.167
201803 10.316 101.700 12.294
201806 9.276 102.300 10.990
201809 8.445 102.400 9.995
201812 7.561 102.100 8.975
201903 17.256 102.900 20.325
201906 16.044 102.900 18.897
201909 15.247 102.900 17.959
201912 13.826 102.900 16.285
202003 12.638 103.300 14.828
202006 11.114 103.200 13.052
202009 20.983 103.500 24.571
202012 18.983 103.400 22.251
202103 17.755 104.300 20.632
202106 15.367 105.000 17.738
202109 20.551 105.800 23.542
202112 17.584 106.600 19.992
202203 13.278 109.900 14.643
202206 11.513 113.600 12.283
202209 7.840 116.400 8.163
202212 4.881 115.900 5.104
202303 3.184 117.300 3.290
202306 1.242 116.400 1.293
202309 -1.386 117.400 -1.431
202312 -2.806 116.700 -2.914
202403 -4.531 118.400 -4.638
202406 -6.027 118.500 -6.164
202409 -1.807 118.900 -1.842
202412 -1.850 118.900 -1.886
202503 -3.399 120.200 -3.427
202506 -3.573 120.700 -3.588
202509 -3.344 121.600 -3.333
202512 -3.106 121.200 -3.106
202603 9.131 121.200 9.131

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $8.40 mean?
Ascendis Pharma AS (ASND) has a Cyclically Adjusted Book per Share of $8.40 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Ascendis Pharma AS and its competitors.
Is Ascendis Pharma AS's Cyclically Adjusted Book per Share too high?
Ascendis Pharma AS's current Cyclically Adjusted Book per Share is $8.40. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's Cyclically Adjusted Book per Share compare to SMMT and BBIO?
Ascendis Pharma AS's Cyclically Adjusted Book per Share of $8.40 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Ascendis Pharma AS and its competitors. Ascendis Pharma AS's current Cyclically Adjusted Book per Share is $8.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (ASND) has a current Cyclically Adjusted Book per Share of $8.40. The current Cyclically Adjusted Book per Share is $8.40. Ascendis Pharma AS's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Ascendis Pharma AS (ASND), the current Cyclically Adjusted Book per Share is $8.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascendis Pharma AS Business Description

Other Exchanges A1SN34:Brazil
Address Tuborg Boulevard 12, Hellerup, DNK, 2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score

Get the complete analysis for ASND

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$260.75
Price